Evidence map›Paper›PMID 32085394›Full record

Trial reportNutrients2020

Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans.

Shane P P Ryan, Alissa A Newman, Jessie R Wilburn, Lauren D Rhoades, S Raj J Trikha, Ellen C Godwin, Hayden M Schoenberg, Micah L Battson, Taylor R Ewell, Gary J Luckasen and 3 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. SGLT2 inhibitors: Beyond glycemic control.Journal of clinical & translational endocrinology · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shane P P RyanDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Alissa A NewmanDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Jessie R WilburnDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Lauren D RhoadesDepartment of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO 80523, USA.
S Raj J TrikhaDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Ellen C GodwinDepartment of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO 80523, USA.
Hayden M SchoenbergDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Micah L BattsonDepartment of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO 80523, USA.
Taylor R EwellDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-8220-9745
Gary J LuckasenMedical Center of the Rockies Foundation, University of Colorado Health, Loveland, CO 80538, USA.
Laurie M BielaDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Christopher L MelbyDepartment of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0003-2478-1844
Christopher BellDepartment of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523, USA.
Colorado State University · USColorado Health Foundation · US

Funding

AstraZeneca Pharmaceuticals LP ISSDAPA0009
6 · The paper itself

Abstract

Sedentary obesity is associated with increased risk of many cardio-metabolic diseases, including type 2 diabetes. Weight loss is therefore a desirable goal for sedentary adults with obesity. Weight loss is also a well-documented side effect of sodium glucose co-transporter 2 (SGLT2) inhibition, a pharmaceutical strategy for diabetes treatment. We hypothesized that, compared with placebo, SGLT2 inhibition as an adjunct to out-patient dietary counselling for weight loss would lead to more favorable modification of body mass and composition, and greater improvement in glucose regulation and lipid profile. Using a randomized, double-blind, repeated measures parallel design, 50 sedentary men and women (body mass index: 33.4 ± 4.7 kg/m

Indexed as

Diet, ReducingDirective CounselingWeight Reduction ProgramsAdolescentAdultAgedBenzhydryl CompoundsBody Fat DistributionBody Mass IndexDouble-Blind MethodFemaleGlucoseGlucosidesHumansLipoproteins, VLDLMaleBenzhydryl CompoundsdapagliflozinGlucoseGlucosidesLipoproteins, VLDLSodium-Glucose Transporter 2 InhibitorsTriglyceridesbody compositiondiabetesSGLT2weight loss

Identifiers

PMID32085394
PMCPMC7071188
OpenAlexW3008274487

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.